Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$41M
- −15.0% YoY
- EPS (diluted)
- −$0.37
- +11.9% YoY
Source: XBRL data from the Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 10-Q on SEC EDGAR. USD.
Amylyx Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue not disclosed; net loss $41.3M vs $35.9M YoY
- Operating margin not applicable; operating loss $43.8M vs $37.8M YoY
- Avexitide R&D $10.0M, up 84%; AMX0035-PSP $0.6M, down 86%
- Cash, equivalents and marketable securities $279.8M at March 31, 2026; funding expected into 2028
- LUCIDITY enrollment complete; topline data expected Q3 2026 and potential commercial launch in 2027
Risk Factors
- Newly added macroeconomic risk: evolving U.S. government policies, geopolitical conflicts, inflation, and interest-rate changes
- Most material financial update: cash, cash equivalents, and marketable securities expected to fund operations into 2028
- Regulatory risk: OBBBA changes to Medicaid, Medicare, and Marketplace eligibility could reduce served patient populations
- Operational risk: failure of avexitide or AMX0035 development, approval, or commercialization could materially harm the business
- Financial risk: accumulated deficit reached $792.7 million as of March 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amylyx Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.